We are an international biotech company committed to our goal of improving the lives of patients through innovative and differentiated antibody therapeutics.read more
Judith Klimovsky, M.D. ā Executive Vice President & Chief Development Officer at Genmab
Executive Bio
Dr. Klimovsky joined Genmab in 2017 and is a recognized drug developer with more than 20 years of experience in R&D leadership roles in big pharma. She has successfully led the development of key cancer drugs at both Bristol Myers Squibb and Novartis, from early clinic through late-stage development and approval including ixabepilone (BMS), ASA404, MEK162, LGX818 and Afinitor (Novartis). During the span of her career, she has led global development organizations of over 450 people.
Previously, Dr. Klimovsky served in various hematology clinical practice positions in Buenos Aires, Argentina. Dr. Klimovsky earned her M.D. from the Buenos Aires University School of Medicine. As a medical doctor, she also brings skills and experience from working as a clinician in hospital environments.
Dr. Klimovsky has been a member of the Board of Directors of Bio-Techne since April 2024.
Executive Team Culture Ratings from Genmab Employees
TOP
30%
Genmab's Executive Team scores in the Top 30% of similar sized companies on Comparably